Form 4: Envoy Medical Director Acquires New Stock Options

Envoy Medical Director Susan Kantor reported the acquisition of 62,500 stock options and beneficial ownership of 77,887 Class A Common Stock shares.

Summary

• Susan Kantor, a Director at Envoy Medical, Inc. (COCH), reported changes in her beneficial ownership of company securities.
• She directly beneficially owns 77,887 shares of Class A Common Stock.
• She holds existing stock options to purchase 62,500 shares of Class A Common Stock at an exercise price of $2.40, which began vesting on October 15, 2024, and expire on October 15, 2033.
• On December 3, 2025, she acquired an additional 62,500 stock options to purchase Class A Common Stock at an exercise price of $0.813.
• These newly acquired options become exercisable on May 1, 2026, and have an expiration date of December 3, 2035.

Sentiment

Score: 6

Explanation: The filing reports a director's acquisition of stock options, which is generally viewed as a positive signal of management's alignment with shareholder interests, though it is a standard compensation event and not indicative of operational performance.

Positives

• The acquisition of 62,500 stock options by a director indicates continued alignment of management's interests with those of shareholders.
• The newly acquired options have a lower exercise price of $0.813 compared to previously held options at $2.40, potentially offering greater upside if the company's stock price appreciates.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, as it is solely focused on insider transactions.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide information directly related to broader industry trends or competitive landscape within the medical device sector.

Stakeholder Impact

• Shareholders: The acquisition of stock options by a director may be perceived as a positive signal of confidence in the company's future, aligning management's incentives with shareholder value creation.

Next Steps

• Continued vesting of the remaining 46,875 shares of stock options (exercise price $2.40) pro rata on the 15th of each month for 36 consecutive months after October 15, 2024.
• Potential exercise of stock options by Susan Kantor, subject to their respective vesting schedules and expiration dates.

Key Dates

Keywords

Envoy Medical, COCH, Form 4, Insider Transaction, Stock Options, Director, Beneficial Ownership